A Phase I Study of Obatoclax Mesylate, a BCL-2 Antagonist, Plus Topotecan in Solid Tumor Malignancies

Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-010-1265-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients With Advanced Solid Tumors or Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2010English

OA12 a Phase I Study of Novel BCL-2/BCL-xL Inhibitor APG-1252 in Patients With Advanced SCLC or Other Solid Tumor

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A Phase I Study of Weekly Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

Oncologist
Cancer ResearchMedicineOncology
2010English

A Phase I and Pharmacokinetic Study of Intraperitoneal Topotecan

British Journal of Cancer
Cancer ResearchOncology
2001English

A Phase 1 Study of Cetuximab and Lapatinib in Patients With Advanced Solid Tumor Malignancies

Cancer
Cancer ResearchOncology
2015English

Phase I Study of a Novel Taxane BMS-188797 in Adult Patients With Solid Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2005English

A Phase I Study of Paclitaxel, Topotecan, Cisplatin and Filgrastim in Patients With Newly Diagnosed Advanced Ovarian Epithelial Malignancies: A Gynecologic Oncology Group Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2007English

Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Phase I Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy